Insider Transactions Reported by 16 Insiders of Monopar Therapeutics

Symbol
MNPR on Nasdaq
Location
Wilmette, IL

Insiders trading volume in the past year

Monopar Therapeutics executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Hendricks Diane 10%+ Owner $50,213,802 16 Dec 2025
Tactic Pharma LLC 10%+ Owner $17,303,519 -$36,166,647 -68% 24 Sep 2025
Chandler Robinson Chief Executive Officer, Director $13,145,033 -$672,020 -4.9% 31 Dec 2025
Andrew Cittadine Chief Operating Officer $4,448,817 31 Dec 2025
ARTHUR J. KLAUSNER Director $1,228,229 -$343,889 -22% 18 Dec 2025
CHRISTOPHER M. STARR Director $541,067 -$672,020 -55% 02 Dec 2025
Kim R. Tsuchimoto Director $459,453 -$356,171 -44% 02 Dec 2025
Lavina Talukdar Director $308,022 02 Dec 2025
Michael J. Brown Director $136,941 31 Dec 2023
Quan Vu Chief Financial Officer $104,925 +$104,925 26 Dec 2025
Andrew Paul Mazar Chief Scientific Officer, Director $94,434 31 Mar 2022
Karthik Radhakrishnan Chief Financial Officer $10,447 28 Oct 2024
TacticGem LLC 10%+ Owner $0 09 Dec 2024
Raymond Anderson Director 02 Dec 2025
PATRICE RIOUX Acting Chief Medical Officer 01 Jan 2026
Jose Octavio Pinto Costa Filho Chief Medical Officer 12 Jul 2021

Recent Insider Transactions by Companies or Individuals for Monopar Therapeutics

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.